NEW YORK--(BUSINESS WIRE)--Schrödinger, a privately held company revolutionizing drug discovery and materials design through advanced molecular simulations, today announced the appointment of veteran pharmaceutical executive Joel Lebowitz as chief financial officer. Mr. Lebowitz, a longtime senior executive at Merck, brings to the company deep experience in finance and business development.
“Joel brings a wealth of experience to Schrödinger at a time when we are expanding our drug discovery programs in partnership with leading biopharma teams around the world,” said Ramy Farid, Ph.D., Schrödinger’s president and CEO. “We look forward to working with him as we enter an exciting new period of growth. We’ve demonstrated the power of our advanced computing platform, and Joel’s vast experience in business development, portfolio analysis, and pipeline valuation will help us achieve continued success.”
“I’m thrilled to be joining the talented team at Schrödinger,” Mr. Lebowitz said. “I’m looking forward to supporting our mission to improve human health and quality of life through the continued growth of our software business as well as by realizing the value from our ever-expanding pipeline of early- stage assets.”
Before joining Schrödinger, Mr. Lebowitz spent much of his career at Merck, serving most recently as global finance lead, project management. In that role, he led a global finance team in the successful divestiture of the Merck Consumer Care division. He also spent three years as Merck’s executive director for pipeline valuation and portfolio analysis, leading the group responsible for optimizing research investment and supporting portfolio planning and prioritization. Mr. Lebowitz’s other roles at Merck included executive director, corporate planning and management reporting, a position that gave him responsibility for developing the company’s budget, revenue forecasts, and long-range operating plan, and senior director, business development. Mr. Lebowitz earned a B.A. in applied mathematics and economics from Brown University and an MBA in finance and international business from Columbia University.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schrödinger has a growing pipeline of early stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. In addition, the company has deep partnerships and collaborations in such fields as biotechnology, pharmaceuticals, chemicals, and electronics. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Founded in 1990, Schrödinger has nearly 400 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.Schrödinger.com.